RAJYALAKSHMI LUTHRA to Tumor Suppressor Protein p53
This is a "connection" page, showing publications RAJYALAKSHMI LUTHRA has written about Tumor Suppressor Protein p53.
Connection Strength
0.647
-
Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J. 2021 03 06; 11(3):52.
Score: 0.078
-
Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations. BMC Cancer. 2020 Jan 31; 20(1):83.
Score: 0.072
-
RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD. Cancer Med. 2020 02; 9(3):849-858.
Score: 0.072
-
TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. Ann Diagn Pathol. 2019 Aug; 41:38-42.
Score: 0.069
-
DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol. 2019 07; 94(7):757-766.
Score: 0.069
-
Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption. Hum Pathol. 2018 12; 82:215-231.
Score: 0.065
-
TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol. 2015 May 08; 8:45.
Score: 0.052
-
Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2644-51.
Score: 0.051
-
COLD-PCR finds hot application in mutation analysis. Clin Chem. 2009 Dec; 55(12):2077-8.
Score: 0.035
-
Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy. Mol Cancer Ther. 2018 07; 17(7):1575-1584.
Score: 0.016
-
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer. 2017 Oct 01; 123(19):3717-3724.
Score: 0.015
-
Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma. Thyroid. 2017 01; 27(1):81-87.
Score: 0.015
-
Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma. J Pathol. 2016 09; 240(1):84-95.
Score: 0.014
-
Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations. J Cutan Pathol. 2015 May; 42(5):308-17.
Score: 0.013
-
Mucinous and nonmucinous appendiceal adenocarcinomas: different clinicopathological features but similar genetic alterations. Mod Pathol. 2002 Jun; 15(6):599-605.
Score: 0.005
-
TabBO: a model reflecting common molecular features of androgen-independent prostate cancer. Clin Cancer Res. 2000 Mar; 6(3):1190-7.
Score: 0.005